K
Keith M. Sullivan
Researcher at Duke University
Publications - 458
Citations - 40788
Keith M. Sullivan is an academic researcher from Duke University. The author has contributed to research in topics: Transplantation & Total body irradiation. The author has an hindex of 105, co-authored 447 publications receiving 39067 citations. Previous affiliations of Keith M. Sullivan include American Cancer Society & Boston Children's Hospital.
Papers
More filters
Journal ArticleDOI
Conditional and unconditional estimation of multidimensional quality of life after hematopoietic stem cell transplantation: a longitudinal follow-up of 415 patients.
TL;DR: Most patients really do experience good levels of QOL in the 4 years after bone marrow transplantation, and typical patients can look forward to a QOL after transplantation that is broadly comparable to that of the normal population.
Journal Article
Graft versus leukemia effect in man: the relapse rate of acute leukemia is lower after allogeneic than after syngeneic marrow transplantation.
TL;DR: The results confirm the circumstantial evidence for a GVL effect exerted by allogeneic marrow andalyses are in progress to determine whether aGVL effect exists in subsets of patients as a function of their particular diagnosis or status at the time of BMT.
Journal ArticleDOI
Cataracts after bone marrow transplantation: Long-term follow-up of adults treated with fractionated total body irradiation
M C Benyunes,M C Benyunes,Keith M. Sullivan,Keith M. Sullivan,H. Joachim Deeg,H. Joachim Deeg,Motomi Mori,Motomi Mori,Wally Meyer,Wally Meyer,L D Fisher,L D Fisher,Richard Benisnger,Richard Benisnger,Marious K. Jack,Marious K. Jack,John Hicks,John Hicks,Robert P. Witherspoon,Robert P. Witherspoon,C. Dean Buckner,C. Dean Buckner,John A. Hansen,John A. Hansen,Frederick R. Appelbaum,Frederick R. Appelbaum,Rainer Storb,Rainer Storb +27 more
TL;DR: In this article, the risk of cataracts was determined for groups of patients with respect to the type of preparative regimen received and other preransplant and posttransplant variables.
Journal ArticleDOI
Ursodeoxycholic acid treatment of refractory chronic graft-versus-host disease of the liver.
Ronald H. Fried,Carol S. Murakami,Lloyd D. Fisher,Lloyd D. Fisher,Richard A. Willson,Keith M. Sullivan,Keith M. Sullivan,George B. McDonald,George B. McDonald +8 more
TL;DR: Therapy with UDCA was safe, well-tolerated, and efficacious in the short-term treatment of refractory chronic GVHD of the liver.
Journal ArticleDOI
Association between pretransplant interferon-α and outcome after unrelated donor marrow transplantation for chronic myelogenous leukemia in chronic phase
A. James Morton,Ted Gooley,John A. Hansen,Frederick R. Appelbaum,Barbara Bruemmer,Jean W. Bjerke,Reg Clift,Paul J. Martin,Effie W. Petersdorf,Jean E. Sanders,Rainer Storb,Keith M. Sullivan,Ann E. Woolfrey,Claudio Anasetti +13 more
TL;DR: Pretransplant IFN-α therapy administered for ≥6 months was associated with an increased risk of severe (grades III-IV) acute graft-versus-host disease and mortality in patients with severe acute GVHD refractory to immunosuppressive therapy.